Stefanie D Krämer1, Thomas Betzel1, Linjing Mu2, Ahmed Haider1, Adrienne Müller Herde1, Anna K Boninsegni1, Claudia Keller1, Marina Szermerski3, Roger Schibli1, Bernhard Wünsch3, Simon M Ametamey4. 1. Radiopharmaceutical Science, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland. 2. Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland; and. 3. Institute for Pharmaceutical and Medicinal Chemistry, University of Munster, Munster, Germany. 4. Radiopharmaceutical Science, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland simon.ametamey@pharma.ethz.ch.
Abstract
Clinical and preclinical research with modulators at the N-methyl-d-aspartate (NMDA) receptor GluN2B N-terminal domain (NTD) aims for the treatment of various neurologic diseases. The interpretation of the results is hampered by the lack of a suitable NMDA PET tracer for assessing the receptor occupancy of potential drugs. We have developed 11C-Me-NB1 as a PET tracer for imaging GluN1/GluN2B-containing NMDA receptors and used it to investigate in rats the dose-dependent receptor occupancy of eliprodil, a GluN2B NTD modulator. Methods: 11C-Me-NB1 was synthesized and characterized by in vitro displacement binding experiments with rat brain membranes, in vitro autoradiography, and blocking and displacement experiments by PET and PET kinetic modeling. Receptor occupancy by eliprodil was studied by PET with 11C-Me-NB1. Results: 11C-Me-NB1 was synthesized at 290 ± 90 GBq/μmol molar activity, 7.4 ± 1.9 GBq total activity at the end of synthesis (n = 17), and more than 99% radiochemical purity. 11C-Me-NB1 binding in rat brain was blocked in vitro and in vivo by the NTD modulators Ro-25-6981 and eliprodil. Half-maximal receptor occupancy by eliprodil occurred at 1.5 μg/kg. At 1 mg/kg of eliprodil, a dose with reported neuroprotective effects, more than 99.5% of binding sites were occupied. In vitro, 11C-Me-NB1 binding was independent of the σ-1 receptor (Sigma1R), and the Sigma1R agonist (+)-pentazocine did not compete for high-affinity binding. In vivo, a 2.5 mg/kg dose of (+)-pentazocine abolished 11C-Me-NB1-specific binding, indicating an indirect effect of Sigma1R on 11C-Me-NB1 binding. Conclusion: 11C-Me-NB1 is suitable for the in vivo imaging of NMDA GluN1/GluN2B receptors and the assessment of receptor occupancy by NTD modulators. GluN1/GluN2B NMDA receptors are fully occupied at neuroprotective doses of eliprodil. Furthermore, 11C-Me-NB1 enables imaging of GluN1/GluN2B NMDA receptor cross talk.
Clinical and preclinical research with modulators at the N-methyl-d-aspartate (NMDA) receptor GluN2B N-terminal domain (NTD) aims for the treatment of various neurologic diseases. The interpretation of the results is hampered by the lack of a suitable NMDA PET tracer for assessing the receptor occupancy of potential drugs. We have developed 11C-Me-NB1 as a PET tracer for imaging GluN1/GluN2B-containing NMDA receptors and used it to investigate in rats the dose-dependent receptor occupancy of eliprodil, a GluN2B NTD modulator. Methods:11C-Me-NB1 was synthesized and characterized by in vitro displacement binding experiments with rat brain membranes, in vitro autoradiography, and blocking and displacement experiments by PET and PET kinetic modeling. Receptor occupancy by eliprodil was studied by PET with 11C-Me-NB1. Results:11C-Me-NB1 was synthesized at 290 ± 90 GBq/μmol molar activity, 7.4 ± 1.9 GBq total activity at the end of synthesis (n = 17), and more than 99% radiochemical purity. 11C-Me-NB1 binding in rat brain was blocked in vitro and in vivo by the NTD modulators Ro-25-6981 and eliprodil. Half-maximal receptor occupancy by eliprodil occurred at 1.5 μg/kg. At 1 mg/kg of eliprodil, a dose with reported neuroprotective effects, more than 99.5% of binding sites were occupied. In vitro, 11C-Me-NB1 binding was independent of the σ-1 receptor (Sigma1R), and the Sigma1R agonist (+)-pentazocine did not compete for high-affinity binding. In vivo, a 2.5 mg/kg dose of (+)-pentazocine abolished 11C-Me-NB1-specific binding, indicating an indirect effect of Sigma1R on 11C-Me-NB1 binding. Conclusion:11C-Me-NB1 is suitable for the in vivo imaging of NMDAGluN1/GluN2B receptors and the assessment of receptor occupancy by NTD modulators. GluN1/GluN2BNMDA receptors are fully occupied at neuroprotective doses of eliprodil. Furthermore, 11C-Me-NB1 enables imaging of GluN1/GluN2BNMDA receptor cross talk.
Authors: Hualong Fu; Weiting Tang; Zhen Chen; Vasily V Belov; Genwei Zhang; Tuo Shao; Xiaofei Zhang; Qingzhen Yu; Jian Rong; Xiaoyun Deng; Wei Han; Scott J Myers; Pilar Giffenig; Lu Wang; Lee Josephson; Yihan Shao; April T Davenport; James B Daunais; Mikhail Papisov; Hongjie Yuan; Zijing Li; Stephen F Traynelis; Steven H Liang Journal: ACS Chem Neurosci Date: 2019-02-27 Impact factor: 4.418
Authors: Susan Bengs; Geoffrey I Warnock; Catherine Gebhard; Ahmed Haider; Angela Portmann; Nidaa Mikail; Alexia Rossi; Hazem Ahmed; Dominik Etter; Valerie Treyer; Livio Gisler; Stefanie K Pfister; Caitlin V M L Jie; Alexander Meisel; Claudia Keller; Steven H Liang; Roger Schibli; Linjing Mu; Ronny R Buechel; Philipp A Kaufmann; Simon M Ametamey Journal: J Nucl Cardiol Date: 2022-04-28 Impact factor: 5.952
Authors: Kelly Smart; Ming-Qiang Zheng; Hazem Ahmed; Hanyi Fang; Yuping Xu; Lisheng Cai; Daniel Holden; Michael Kapinos; Ahmed Haider; Zachary Felchner; Jim R Ropchan; Gilles Tamagnan; Robert B Innis; Victor W Pike; Simon M Ametamey; Yiyun Huang; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2022-02-25 Impact factor: 6.960
Authors: Lucas Rischka; Chrysoula Vraka; Verena Pichler; Sazan Rasul; Lukas Nics; Gregor Gryglewski; Patricia Handschuh; Matej Murgaš; Godber M Godbersen; Leo R Silberbauer; Jakob Unterholzner; Christoph Wotawa; Ahmed Haider; Hazem Ahmed; Roger Schibli; Thomas Mindt; Markus Mitterhauser; Wolfgang Wadsak; Andreas Hahn; Rupert Lanzenberger; Marcus Hacker; Simon M Ametamey Journal: J Nucl Med Date: 2021-10-07 Impact factor: 11.082
Authors: Ahmed Haider; Adrienne Müller Herde; Stefanie D Krämer; Jasmine Varisco; Claudia Keller; Katrin Frauenknecht; Yves P Auberson; Louisa Temme; Dina Robaa; Wolfgang Sippl; Roger Schibli; Bernhard Wünsch; Linjing Mu; Simon M Ametamey Journal: J Nucl Med Date: 2019-01-25 Impact factor: 10.057
Authors: Jasper van der Aart; Maqsood Yaqub; Esther J M Kooijman; Jaco Bakker; Jan A M Langermans; Robert C Schuit; Mark B M Hofman; Johannes A M Christiaans; Adriaan A Lammertsma; Albert D Windhorst; Bart N M van Berckel Journal: Mol Imaging Biol Date: 2019-08 Impact factor: 3.488
Authors: Lisheng Cai; Jeih-San Liow; Cheryl L Morse; Sanjay Telu; Riley Davies; Michael P Frankland; Sami S Zoghbi; Ken Cheng; Matthew D Hall; Robert B Innis; Victor W Pike Journal: J Nucl Med Date: 2020-01-10 Impact factor: 10.057
Authors: Ahmed Haider; Irina Iten; Hazem Ahmed; Adrienne Müller Herder; Stefan Gruber; Stefanie D Krämer; Claudia Keller; Roger Schibli; Bernhard Wünsch; Linjing Mu; Simon M Ametamey Journal: J Nucl Med Date: 2018-07-20 Impact factor: 10.057